11 aug: De bedste amerikanske karrierebyer
12 aug: Store, fristende landejendomme
11-08-2008 22:03:00

Nortech Systems Achieves ISO 13485 Quality Certification

Nortech Systems Incorporated (NASDAQ: NSYS) announced it has achieved

ISO 13485 quality certification for its electronics manufacturing

services (EMS) facilities in Merrifield and Baxter, Minn. This

certification allows Nortech to further demonstrate its ability to

provide products and related services to the medical industry that

consistently meet customer and regulatory requirements.

"The medical market continues to show strong growth and we believe this

new ISO certification positions us to capitalize on additional

business," said Mike Degen, president and CEO of Nortech Systems. The

market research firm Technology Forecasters expects medical

opportunities for EMS companies like Nortech to increase 17 percent

annually through 2010, the fastest growth of any market sector.

According to Degen, Nortech Systems has already been proudly assisting

numerous medical OEMs with the production of their non-invasive

equipment, including potentially life-sustaining devices. "This

certification validates and reinforces the critical supporting role

we´ve been playing for our customers all along," he commented.

Based on the ISO 9001 international quality standard, ISO 13485 includes

additional analysis of risk, safety and regulatory requirements. It also

corresponds to a comparable standard of the U.S. Food & Drug

Administration. All Nortech facilities are certified to ISO 9001:2001

standards and the company also employs an enterprise-wide lean

manufacturing initiative utilizing tools such as kaizen, Six Sigma,

rapid action, Balanced Scorecard and 5S.

Fortune Small Business magazine recently ranked Nortech Systems on its

list of "America´s 100 Fastest-Growing Small Public Companies."

About Nortech Systems, Incorporated

Nortech Systems Incorporated (www.nortechsys.com),

based in Wayzata, Minn., is a full-service electronics manufacturing

services (EMS) provider of wire and cable assemblies, printed circuit

board assemblies, and higher-level complete box build assemblies for a

wide range of industries. Markets served include industrial equipment,

military/defense, medical and transportation.

The company has manufacturing capabilities and operating partners in the

U.S., Asia and Latin America. Nortech Systems Incorporated is traded on

the NASDAQ Stock Market under the symbol NSYS.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to

the safe harbor provision of the Private Securities Litigation Reform

Act of 1995. While this release is based on managements

best judgment and current expectations, actual results may differ and

involve a number of risks and uncertainties. Important factors that

could cause actual results to differ materially from the forward-looking

statements include, without limitation: volatility in market conditions

which may affect market supply of and demand for the companys

products; increased competition; changes in the reliability and

efficiency of operating facilities or those of third parties; risks

related to availability of labor; commodity and energy cost instability;

general economic, financial and business conditions that could affect

the companys financial condition and results

of operations; as well as risk factors listed from time to time in the

companys filings with the SEC.

Brookside Communications Group

Warren Djerf, 952-920-3908

warren@brookcomm.net

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
16
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
11:53
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
15
06 dec
 
Baronen, du har længe haft Bitcoin siger du? Men har først nævnt det herinde 13/10-2017?   Tror du v..
15
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Genmab/IR: Royalties vil som minimum dække omkostningerne næste år

12-12-2017 14:04:43
Genmabs royaltyindtægter fra salget af selskabets kræftmidler vil i 2018 som minimum dække omkostningerne.Det præciserer Genmabs IR- og kommunikationsdirektør, Rachel Curtis Gravesen, i en e-mail over for Ritzau Finans, efter at selskabet i nattens løb er kommet med en foreløbig prognose for 2018, som angiveligt har givet anledning til en del tolkning i analytikerkredse vedrørende salget af Genmab..

Aktier/middag: Genmab ryger ned på usikkerhed om 2018-forventninger

12-12-2017 11:39:38
Genmab er under hårdt pres på det danske aktiemarked tirsdag, da flere investorer har tolket negativt på ledelsens udmeldinger om 2018 og nu regner med et lavere salg af kræftmidlet Darzalex end tidligere.Aktien dykker 7,7 pct. til 1093 kr. - det største fald i små to år - og nedturen for biotekaktien er med til at tynge C20 Cap-indekset, som dykker 0,3 pct. til 1125,54.Genmab afholdt natten til t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
2
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen
3
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen - NY
4
Genmab/IR: Royalties vil som minimum dække omkostningerne næste år
5
Novo-rival for godkendt kopiprodukt

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 19:01:47
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB3 - 2017-12-12 19:01:47 - 2017-12-12 19:01:47 - 1 - Website: OKAY